TABLE 3.

Cost parameters.

		China				United StatesUS
		Cost ($)	Range ($)	Dis	Source	Cost ($)	Range ($)	Dis	Source
Drugs costs	Olaparib/cycle	7,515.2	5,636.4–9,394	T	Yaozhi network (XXX)	13,886	10,414.5–17,357.5	T	Rawla et al. (2019)
AEs costs	Thrombocytopenia/unit	23.25	18.6–27.9	T	Zhou et al. (2016)	732.3	585.84–878.76	T	Guy et al. (2019)
	Neutropenia/unit	58.07	46.456–69.684	T	Zhou et al. (2016)	867.98	694.384–1,041.576	T	Guy et al. (2019)
	Fatigue/unit	0	0	T	Zhou et al. (2016)	0	0	T	Guy et al. (2019)
	Vomiting/unit	3.66	2.928–4.392	T	Zhou et al. (2016)	678.24	525.592–813.888	T	Guy et al. (2019)
	Anemia/unit	0	0	T	Zhou et al. (2016)	755.92	604.736–907.104	T	Guy et al. (2019)
Follow-up tests costs	Biochemical test/cycle	25.39	20.312–30.468	T	Hospital charges	72.43	50.70–94.16	T	Guy et al. (2019)
	Blood routine examination/cycle	3.53	2.824–4.236	T	Hospital charges	15.23	9.85–21.75	T	Guy et al. (2019)
	CT/cycle	94.58	75.664–113.496	T	Hospital charges	541.7	350.56–773.77	T	Guy et al. (2019)
BSC cost		117.12	93.69–140.54	T	Wu et al. (2014)	684.31	547.448–821.172	T	Gharaibeh et al. (2018)
Terminal care cost		1948.42	1,558.74–2,338.10	T	Wu et al. (2014)	85,904	55,592–122705	T	Guy et al. (2019)

Abbreviations: BSC, best support care; AEs, adverse events.